31 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
An unprecedented dual antagonist and agonist of human Transglutaminase 2.
Stanford University
(±) cis-Bisamido epoxides: A novel series of potent FXIII-A inhibitors.
University of Leeds
Imidazolium-based warheads strongly influence activity of water-soluble peptidic transglutaminase inhibitors.
Aston University
Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.
Evotec (Uk)
SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's Disease.
TBA
Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's Disease.
TBA
Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2.
Stanford University
Mechanisms, biology and inhibitors of deubiquitinating enzymes.
Institute For Bio-Medical Research
Structure-based design of alpha-amido aldehyde containing gluten peptide analogues as modulators of HLA-DQ2 and transglutaminase 2.
Stanford University
Development and Utilization of Novel Transglutaminase 2 Inhibitors for Potential Treatment of Autoimmune Disease and Gastrointestinal Disorder.
Usona Institute
Discovery and Characterization of PROTACs Targeting Tissue Transglutaminase (TG2).
Northwestern University
Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles.
Stanford University
Factor XIIIa inhibitors as potential novel drugs for venous thromboembolism.
Xavier University of Louisiana
The war on hTG2: warhead optimization in small molecule human tissue transglutaminase inhibitors.
University of Ottawa
The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington's Disease.
Aligarh Muslim University
Structure-activity relationships of N-terminal variants of peptidomimetic tissue transglutaminase inhibitors.
University of Ottawa
Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions.
National Institute of Pharmaceutical Education and Research (NIPER)
Structure-activity relationship study of novel tissue transglutaminase inhibitors.
Harvard Medical School
Structure-activity relationships of hydrophobic alkyl acrylamides as tissue transglutaminase inhibitors.
University of Ottawa
Hydroxy-substituted trans-cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease.
Alma Mater Studiorum-University of Bologna
Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors.
Daegu-Gyeongbuk Medical Innovation Foundation (Dgmif)
Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase.
University of Ottawa
Uridine-based inhibitors as new leads for antibiotics targeting Escherichia coli LpxC.
Duke University
N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.
Pudue Pharma Discovery Research